格列齊特

格列齊特
臨床資料
商品名（英語：Drug nomenclature）	達美康
AHFS/Drugs.com	Micromedex詳細消費者藥物信息
懷孕分級	澳: C ; ;
給藥途徑	口服
ATC碼	A10BB09 (WHO) ;
法律規範狀態
法律規範	澳：限醫生處方（S4）;
藥物動力學數據
生物半衰期	10.4小時
識別資訊
	IUPAC命名法 N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide; ;
CAS號	21187-98-4
PubChem CID	3475;
DrugBank	DB01120 ;
ChemSpider	3356 ;
UNII	G4PX8C4HKV;
KEGG	D01599 ;
ChEBI	CHEBI:31654 ;
ChEMBL	ChEMBL427216 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID9023095 ;
ECHA InfoCard	100.040.221
化學資訊
化學式	C15H21N3O3S
摩爾質量	323.412 g/mol
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES O=S(=O)(c1ccc(cc1)C)NC(=O)NN3CC2CCCC2C3;
	InChI InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19) ; Key:BOVGTQGAOIONJV-UHFFFAOYSA-N ;

格列齊特（英語：Gliclazide），商品名為達美康。是一種磺酰脲類口服抗糖尿病藥。 ^[1]^[2]. 格列齊特可以防止因高血糖引起的細胞凋亡，保護人體的胰島β細胞。^[3] 格列齊特還可以防止因2型糖尿病導致的動脈粥樣硬化（防止動脈脂肪堆積）。^[4]格列齊特在中國作為一線藥物使用，應用極為廣泛，而在其他國家卻並不常用。Diamicron ( Gliclazide)

Quick Facts 臨床資料, 商品名（英語：Drug nomenclature） ...

Close

藥理

格列齊特為胰島素增泌劑，通過抑制胰島β細胞的ATP-sensitive potassium channel（英語：ATP-sensitive potassium channel），從而促進胰島素的釋放。

引用

[1]
Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. 1990, 8 (2): 109–14. PMID 2106423. doi:10.1016/0168-8227(90)90020-T.
[2]
Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. 2006, 55 (6): 722–30. PMID 16713429. doi:10.1016/j.metabol.2006.01.019.
[3]
Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680.
[4]
Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8.

[pmid2106423-1] [1]
Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. 1990, 8 (2): 109–14. PMID 2106423. doi:10.1016/0168-8227(90)90020-T.

[2] [2]
Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. 2006, 55 (6): 722–30. PMID 16713429. doi:10.1016/j.metabol.2006.01.019.

[3] [3]
Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680.

[4] [4]
Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8.

[1]

[2]

[3]

[4]